五大指南他汀一级预防ASCVD的敏感性、特异性与需治疗人数比较
结果显示CCS、ACC/AHA和NICE指南在相似NNT10下,能更准确地识别后续发生ASCVD的个体。
要点
- CCS、ACC/AHA和NICE指南他汀适用比例高(40%-44%),敏感性68%-70%,特异性59%-63%。
- USPSTF和ESC/EAS指南敏感性较低(57%和24%),但特异性较高(72%和86%)。
- 五部指南NNT10相似:中等强度他汀27-32,高强度他汀18-21。
核心结论
- CCS、ACC/AHA和NICE指南在相似NNT10下,能正确分配他汀治疗给更多后续发生ASCVD的个体,可能优于USPSTF和ESC/EAS指南。
主要发现
- 随访期间观察到4156例ASCVD事件。
- 敏感性:CCS 68%(2815/4156),ACC/AHA 70%(2889/4156),NICE 68%(2815/4156),USPSTF 57%(2377/4156),ESC/EAS 24%(1001/4156)。
- NNT10(中等强度/高强度他汀):CCS 32/21,ACC/AHA 30/20,NICE 30/20,USPSTF 27/18,ESC/EAS 29/20。
关键数值与推荐
- 敏感性、特异性及NNT10计算基于各指南他汀一级预防标准。
- 假设低密度脂蛋白胆固醇每降低38 mg/dL,ASCVD事件相对风险降低25%。
临床怎么用
- 在初级预防中,可优先考虑CCS、ACC/AHA或NICE指南的他汀分配策略,以在相似NNT10下覆盖更多高危个体。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Five major guidelines on statin use for primary prevention of atherosclerotic cardiovascular disease (ASCVD) have been published since 2014: the National Institute for Health and Care Excellence (NICE; 2014), US Preventive Services Task Force (USPSTF; 2016), Canadian Cardiovascular Society (CCS; 2016), European Society of Cardiology/European Atherosclerosis Society (ESC/EAS; 2016), and American College of Cardiology/American Heart Association (ACC/AHA; 2018). OBJECTIVE: To compare the sensitivity, specificity, and estimated number needed to treat (NNT10) to prevent 1 ASCVD event in 10 years according to statin criteria from the 5 guidelines. DESIGN, SETTING, AND PARTICIPANTS: Population-based contemporary cohort study. Analyses were performed in the Copenhagen General Population Study, with a mean follow-up time of 10.9 years. We included 45 750 individuals aged 40 to 75 years. The participants were enrolled between 2003 and 2009 and were all free of ASCVD at baseline. Data were analyzed between January 1, 2019, and August 4, 2019. EXPOSURES: Statin treatment according to guideline criteria. We assumed a 25% relative reduction of ASCVD events per 38 mg/dL (to convert to millimoles per liter, multiply by 0.0259) reduction in low-density lipoprotein cholesterol. MAIN OUTCOMES AND MEASURES: Sensitivity and specificity for ASCVD events and the NNT10 to prevent 1 ASCVD event according to guideline criteria. RESULTS: Median age at baseline examination was 56 years, and 43% of participants were men (n = 19 870 of 45 750). During follow-up, we observed 4156 ASCVD events. Overall, 44% of individuals in Copenhagen General Population Study were statin eligible with CCS (n = 19 953 of 45 750), 42% with ACC/AHA (n = 19 400 of 45 750), 40% with NICE (n = 19 400 of 45 750), 31% with USPSTF (n = 13 966 of 45 750), and 15% with ESC/EAS (n = 6870 of 45 750). Sensitivity and specificity for ASCVD events were 68% (n = 2815 of 4156) and 59% (n = 24 456 of 41 594) for CCS, 70% (n = 2889 of 4156) and 60% (n = 25 083 of 41 594) for ACC/AHA, 68% (n = 2815 of 4156) and 63% (n = 26 213 of 41 594) for NICE, 57% (n = 2377 of 4156) and 72% (n = 30 005 of 41 594) for USPSTF, and 24% (n = 1001 of 4156) and 86% (n = 35 725 of 41 594) for ESC/EAS. The NNT10 to prevent 1 ASCVD using moderate-intensity and high-intensity statin therapy, respectively, was 32 and 21 for CCS criteria, 30 and 20 for ACC/AHA criteria, 30 and 20 for NICE criteria, 27 and 18 for USPSTF criteria, and 29 and 20 for ESC/EAS criteria. CONCLUSIONS AND RELEVANCE: With similar NNT10 to prevent 1 event, the CCS, ACC/AHA, and NICE guidelines correctly assign statin therapy to many more of the individuals who later develop ASCVD compared with the USPSTF and ESC/EAS guidelines. Our results therefore suggest that the CCS, ACC/AHA, or NICE guidelines may be preferred for primary prevention.
引用
- Mortensen MB, Nordestgaard BG. Statin Use in Primary Prevention of Atherosclerotic Cardiovascular Disease According to 5 Major Guidelines for Sensitivity, Specificity, and Number Needed to Treat. JAMA Cardiol. 2019. PMID: 31577339. doi:10.1001/jamacardio.2019.3665
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。